Targeting peptides and methods of use

Patent metadata

Field	Value
Publication number	US-10653801-B2
Application number	US-201816188881-A
Country	US
Kind code	B2
Filing date	Nov 13, 2018
Priority date	Aug 4, 2014
Publication date	May 19, 2020
Grant date	May 19, 2020

Abstract

A compound includes at least one targeting peptide coupled to a detectable moiety. The targeting peptide binds to EDB-FN or EDA-FN and includes at least one of amino acid sequence selected from the group consisting of SEQ ID NOs: 1-30.

First claim

Having described the invention, the following is claimed:

1. A method of determining cancer aggressiveness in a subject having or suspected of having cancer, the method comprising:
administering to the subject a molecular probe comprising at least one targeting peptide coupled to a detectable moiety, the targeting peptide binding to EDB-FN or EDA-FN and comprising at least one amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, and SEQ ID NO: 30; and
detecting the molecular probes in the subject, wherein the amount of the probe detected is indicative of the aggressiveness of the cancer.

2. The method of claim 1 , further comprising comparing the amount of probe detected to a control, wherein an increase in the amount of probe detected compared to the control is indicative of the subject having an increased risk of aggressive cancer.

3. The method of claim 1 , the detectable moiety comprising an imaging agent and the probe being detectable upon administration to the subject by at least one of gamma imaging, positron emission tomography (PET) imaging, computer tomography (CT) imaging, magnetic resonance imaging, near infrared imaging, or fluorescent imaging.

4. The method of claim 1 , detectable moiety including at least one of an optical dye, MRI contrast agent, a PET agent, a SPECT agent, a CT contrast agent, radiolabel, or an ultrasound contrast agent.

5. The method of claim 1 , the probe being systemically administered to a subject having or suspected of having cancer.

6. The method of claim 1 , the cancer comprising at least one of breast cancer, liver cancer, stomach cancer, colon cancer, pancreatic cancer, ovarian cancer, lung cancer, kidney cancer, prostate cancer, testicular cancer, glioblastoma, sarcoma, bone cancer, brain cancer, head and neck cancers, or skin cancer.

7. A method of measuring the efficacy of a therapeutic agent in treating cancer in a subject, the method comprising:
administering the therapeutic agent to the subject;
administering a molecular probe to the subject, the molecular probe comprising at least one targeting peptide coupled to a detectable moiety, the targeting peptide binding to EDB-FN or EDA-FN and comprising at least one amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, and SEQ ID NO: 30; and
detecting the molecular probe in the subject.

8. The method of claim 7 , the molecular probe being administered to the subject in a first administration prior to or after administration of the therapeutic agent to define a first location and/or distribution of the cancer, and the molecular probe being administered to the subject in a second administration after the first administration and the administration of the therapeutic to define a second location and/or distribution of the cancer, the first and second location and/or distribution of the cancer being compared to determine the efficacy of the therapeutic agent.

9. The method of claim 7 , the detectable moiety comprising an imaging agent and the probe being detectable upon administration to the subject by at least one of gamma imaging, positron emission tomography (PET) imaging, computer tomography (CT) imaging, magnetic resonance imaging, near infrared imaging, or fluorescent imaging.

10. The method of claim 7 , detectable moiety including at least one of an optical dye, MRI contrast agent, a PET agent, a SPECT agent, a CT contrast agent, radiolabel, or an ultrasound contrast agent.

11. The method of claim 7 , the probe being systemically administered to a subject having cancer.

12. The method of claim 7 , the cancer comprising at least one of breast cancer, liver cancer, stomach cancer, colon cancer, pancreatic cancer, ovarian cancer, lung cancer, kidney cancer, prostate cancer, testicular cancer, glioblastoma, sarcoma, bone cancer, brain cancer, head and neck cancers, or skin cancer.

Assignees

• Univ Case Western Reserve

Inventors

• Lu Zheng-Rong
• Han Zheng
• Zhu Hui

Classifications

• A61K51/082

  the peptide being a RGD-containing peptide · CPC title

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title

• C07K14/78

  Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG] · CPC title

• A61K49/0054

  Macromolecular compounds, i.e. oligomers, polymers, dendrimers · CPC title

• A61K49/0056 Primary

  Peptides, proteins, polyamino acids · CPC title